Cancer stem cell mechanisms and targeted therapeutic strategies in head and neck squamous cell carcinoma
Year: 2025
Type: review
Abstract: Head and neck squamous cell carcinoma (HNSCC) originates in the epithelial lining of the oral cavity, pharynx, and larynx, with over 830,000 new cases diagnosed globally in 2020, making it the seventh most prevalent cancer. Despite treatment advances, high-grade HNSCCs remain associated with poor outcomes and a high risk of recurrence. Although Cancer Stem Cells (CSCs) are rare in HNSCC tumors, they are key drivers of tumor relapses, as they evade apoptosis and survive current therapies through enhanced DNA repair and quiescence. This review integrates recent discoveries into a unified framework for understanding CSC mechanisms. It examines the role of pluripotency factors, biomarkers, replicative immortalization, metabolic reprogramming, redox regulation, and immune evasion in shaping CSC behavior and survival under treatment stress. Non-coding RNAs are also discussed as modulators of gene expression via epigenetic regulation in CSCs. Importantly, it highlights how these adaptive mechanisms intersect as potential vulnerabilities that could be exploited to eliminate CSCs through targeting multiple pathways. Finally, it provides recent and emerging precision therapeutics, including CAR-T cells, immune checkpoint inhibitors, metabolic and redox-targeting agents, and epigenetic modulators currently in preclinical and clinical trials applications designed to eliminate CSCs and improve patient outcomes in HNSCC.
Source: Cancer Letters
Authors: Nagarajan Maharajan, Daniel S. Benyamien-Roufaeil, Robert A. Brown, Benjamin A. Portney, Aditi Banerjee, Michal Zalzman
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: head and neck squamous cell carcinoma, cancer stem cells, tumor recurrence, pluripotency factors, DNA repair, quiescence, metabolic reprogramming, redox regulation, immune evasion, non-coding RNA, epigenetic regulation, chimeric antigen receptor T cells, immune checkpoint inhibitors, epigenetic regulators, precision therapy
Open Access status: hybrid
Estimated APC paid: $4,960
OpenAlex ID: W4413914475
